T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Commentary|Articles|July 14, 2026
Research Rewind: Phase 3 Breast Cancer Data Highlights From Q2 2026
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
Advertisement
Advertisement
Recent months have been filled with breast cancer research highlights from major conferences and more. Need a refresher? We’ve got you covered with this recap of pivotal phase 3 data announcements and highlights, many of which have already changed the breast cancer treatment paradigm across disease subtypes.
Related to this article
Camizestrant plus palbociclib did not significantly improve progression-free survival vs anastrozole plus palbociclib in the first-line SERENA-4 trial.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
The FDA extended the review period for zanzalintinib plus atezolizumab in metastatic colorectal cancer.
Selcodebart improved hemoglobin levels and transfusion independence across 3 anemia cohorts in myelofibrosis, regardless of concomitant JAK inhibitor use.
OS in the LIVERATION trial of namodenoson in advanced HCC appeared longer than anticipated, prompting consideration of an earlier interim analysis.
Micvotabart pelidotin produced a 36% confirmed ORR and a 6.2-month median PFS in pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Advertisement
Advertisement